Manufacturers

Pharma in the field: Barrett's story

Manufacturers

Work worth doing: Innovative field solutions

Manufacturers

Essential skills for outsourced field solutions teams

Manufacturers

Valuing potential cures: An examination of ICER’s approach to assessing high-impact single and short-term therapies

Manufacturers

First 10 drugs for Medicare price negotiation announced under IRA

Manufacturers

Empower your people and brand with biopharma learning solutions

Manufacturers

On-demand webinar: The EU JCA process: Opportunities and challenges in bringing innovative medicines to patients in Europe

Reimbursement considerations for home infusions

Copay accumulator adjustment programs significantly increase patient financial burden

Issue Brief: Assessing the impact of formulary exclusion on healthcare costs and outcomes for patients on therapy for certain chronic conditions

Manufacturers

Recap Asembia 2023: Our impactful contributions to the premier specialty pharmacy conference

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Manufacturers

How to forge stronger working relationships with payers

Manufacturers

Yes, you can commercialize on your own—even if you're an emerging biopharma

Manufacturers

The essential guide to drug commercialization

Manufacturers

New pan-EU HTA: How can biopharma navigate the joint clinical assessment?

Manufacturers

HTA Quarterly | Summer 2023

Manufacturers

HTA Quarterly | Winter 2022

Manufacturers

HTA Quarterly | Winter 2022

Manufacturers

On-demand webinar: You’ve created a good patient support program, now make it great

Closing the Gaps in Pre-Approval Information Exchange to Accelerate Product Success and Patient Access

Manufacturers

HTA Quarterly | Fall 2022

Manufacturers

Culture, people, and an investment in innovation set AmerisourceBergen apart

Manufacturers

Why FormularyDecisions® is the right choice for enterprise biopharma payer engagement 

Alopecia areata: A global perspective of a disease that extends beyond hair loss

The biosimilars marketplace: Part one

Manufacturers

Webinar slides: Navigating Reimbursement and Access Challenges for Novel Cell and Gene Therapies

Research poster: The current impact of ICER assessments on payer decision making

Skyrocketing growth in PBM formulary exclusions continues to raise concerns about patient access

The drug reimbursement environment in Canada: An overview

HTA Quarterly | Spring 2022

Joint clinical assessment in the EU: Pan-European HTA for drugs and medical devices will become reality 

The UK Innovative Licensing and Access Pathway—A new paradigm in market access

The impact of the Build Back Better Act (BBBA) on rare disease innovation

HTA Quarterly | Winter 2021

Is NICE becoming nicer?

Evidence generation and approval of digital health applications in Germany

Telehealth through the lens of value-based care in the US

ASCVD needs innovation

Manufacturers

Building your field reimbursement and access team: The translational experience and skills that matter most

Health disparities and health technology assessment: Current value assessment frameworks fall short

HTA Quarterly | Fall 2021

Elucidating ICER’s methodologies for Unsupported Price Increase assessments  

Equity considerations in US value assessment: Opportunities ahead

Affordability is about more than drug prices

Manufacturers

What manufacturers need to know about reimbursement and patient support for cell and gene therapies

Manufacturers

Navigating the payer landscape for digital therapeutics

Copay accumulators and the impact on patients

Manufacturers

Work worth doing: FormularyDecisions

HTA Quarterly | Summer 2021

Manufacturers

Ebook: Strategic partnerships for unlocking product potential

Manufacturers

Buy-and-bill vs. self-administered: Field services remove barriers across access points

Manufacturers

Strategies for addressing copay accumulators: What manufacturers need to know

Manufacturers

Checklist: Four things to look for in a field services partner

Manufacturers

Launching field services in the midst of COVID-19

Patient forward: comparing ICER and PCORI use of patient feedback

Manufacturers

Pharma in the field: Heather's story

Manufacturers

Webinar: the growing utilization of copay accumulator programs

Patient-Centered Cost Outcomes—Addressing a Gap in Value Assessment

Manufacturers

Pharma in the field: Ashley's story

Manufacturers

Pharma in the field: Tierra's story

HTA Quarterly | Winter 2020

Ushering in a New Era of Antibiotic Innovation With a Netflix-Style Subscription Payment Model

Manufacturers

Ebook: Virtual drug commercialization

AMCP Nexus 2020 Virtual Recap

Manufacturers

PAP 2020 panel recap: Navigating COVID-19

Manufacturers

Is your PIE incomplete?

Webinar: 5 Years of ICER - Insights and Impact on Payers

Case study: Gaining payer attention through digital innovation

Manufacturers

Rethink field services: Three myths keeping access barriers in front of your product

HTA Quarterly | Fall 2020

Manufacturers

Pharma in the field: Sales reps vs. reimbursement and access specialists

Manufacturers

The Future of Payer Engagement: How Pharma Can Break Through

Manufacturers

The Value of Virtual: How Remote Workshops Can Keep Market Access Efforts Moving

Regulatory and Market Access Impact in Europe of the Recent Medical Software Makers Guidance

Emerging Gene Therapies for Hemophilia in the United States—Value Drivers in a Crystal Ball

The Era of mHealth: A Global Perspective

Webinar: Navigating Pre-approval Information Exchange (PIE) and the AMCP Format for Formulary Submissions, Version 4.1

Manufacturers

Distant But Engaged: Transitioning to Virtual Training

Manufacturers

Webinar: Patient Assistance in the Wake of COVID19

Impact of COVID-19 Pandemic on Patient Access Programs

Manufacturers

Video: Removing Barriers for Biosimilars

Making Part D Access Affordable: Revising the Prescription Drug Benefit

Manufacturers

Mind the (Evidence) Gap

Effectively Communicating Pipeline Information to Drive Payers Attention

HTA Quarterly | Fall 2019

Manufacturers

Biosimilars: Launch Insights From the Field

HTA Quarterly | Summer 2019

Review of HTA Frameworks and Decisions for Next-Generation Sequencing in Precision Oncology

Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?

Manufacturers

How Digital Innovation Drives Improved Market Access Strategies

Xcenda Celebrates 25th Anniversary by Launching New Value & Market Access Solutions

HTA Quarterly | Spring 2019

Upending the Medicare Part B Program: The International Pricing Index (IPI) Proposed Model

The Evolving Healthcare Landscape and the Impact on Patient Access and Affordability

Manufacturers

Managing the Growing Expansion of Copay Accumulators

Original Report: Impact Analysis of ICER Formulary Implementation in Medicaid

Diabetes and the Growing Investment in Drugs, Devices, and Diagnostics 

MCDA: Too Much Talk, Too Little Progress?

HTA Quarterly | Winter 2019

Responding to Stakeholder Input: Finding the Patient Voice in ICER's Value Assessments

Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?

Therapeutic Spotlight: Assessments of Emerging Therapies for Tardive Dyskinesia

Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division

HTA Quarterly | Fall 2018

HTA Quarterly | Late Summer 2018

Emerging Trends in PBM Restrictions on Commercial Copay Assistance

Connected Health: The Next Healthcare Frontier

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Top Trends in Health Policy in Canada: Insights from InnomarLive

The European Medicines Agency to Find a New Home After Brexit

Are Emerging Value Frameworks a Path to Implementing Value-Based Pricing?

HTA Quarterly | Summer 2018

Manufacturers

Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

Manufacturers

Seeing the Value and Transparency of Medicare Part B

HTA Quarterly Spring 2018

Implementing Coverage With Evidence Development

Recent Trends in Oncology Appraisal Decisions: NICE vs. SMC

HTA Quarterly Late Summer 2017

HTA Quarterly | Summer 2017

Understanding the Columbian Health Care Market

HTAQ Summer 2017 Duchenne Muscular Dystrophy New and Revitalized Drugs Bring Hope to Patients

Payer Perceptions and Utilization of ICER Value Assessment Framework

HTA Quarterly | Spring 2017

Revisiting the Familiar: Time to Re-evaluate the GVD?

HTA Quarterly | Winter 2017

Indication-specific Pricing: What should manufacturers expect in key markets

HTA Quarterly | Fall 2016

Rapid Access in the US, UK, and France

Analyzing the impact of Medicare Part D for Oncology Patients

Payer Contact in a “Contactless” World: Achieving Early Engagement